Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2017-03-29 Annual Report
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Annual financial report 2016
Annual Report Classification · 100% confidence The document explicitly identifies itself as 'ANNUAL REPORT 2016' in the header and contains a comprehensive table of contents covering financial statements, management reports, corporate governance, and audit opinions. It is a full-length annual report, not an announcement or a summary, and it contains substantive financial data and analysis. FY 2016
2017-03-29 German
EVOTEC FISCAL YEAR RESULTS 2016: LEADING INNOVATION EFFICIENCY & FIRST-IN-CLASS DRUG DISCOVERY
Earnings Release Classification · 100% confidence The document is titled 'EVOTEC FISCAL YEAR RESULTS 2016' and explicitly states it announces 'financial results and corporate updates for the fiscal year ended 31 December 2016.' It contains detailed financial tables, segment performance analysis (EVT Execute and EVT Innovate), balance sheet items (liquidity), income statement details (revenues, EBITDA, R&D expenses), and forward-looking guidance for 2017. This content structure is characteristic of a comprehensive annual financial report, which aligns with the definition of a 10-K, even though the filing source might be a press release format (DGAP-News). Given the depth of the financial review covering the full fiscal year, it represents the core content of the Annual Report. FY 2016
2017-03-28 English
Präsentation FY 2016
Investor Presentation Classification · 100% confidence The document is a detailed slide deck presentation titled 'Innovation efficiency & First-in-class drug discovery' from Evotec. It contains strategic outlooks, business model descriptions (EVT Execute/Innovate), financial performance summaries for 2016, and forward-looking guidance for 2017. It is clearly an investor-facing presentation used to communicate company strategy and financial results, fitting the definition of an Investor Presentation. FY 2016
2017-03-28 English
EVOTEC TO ATTEND THREE UPCOMING INVESTOR CONFERENCES
Report Publication Announcement Classification · 99% confidence The document is a press release titled "EVOTEC TO ATTEND THREE UPCOMING INVESTOR CONFERENCES." It details the dates, locations, and attending management for three distinct investor events (Bankhaus Lampe Deutschlandkonferenz, European Capital Markets Conference, and 10th Kempen & Co Life Sciences Conference). This type of announcement, informing the public about management's schedule for meeting with investors and analysts, is best classified as an Investor Presentation (IP) related activity or, more broadly, a general corporate announcement. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific report (AR, IR), and it directly relates to investor engagement activities, it aligns closely with Investor Presentation (IP) materials, even though it is an announcement *about* attending events where presentations will occur. However, given the options, this is a communication aimed at investors regarding future engagement. If the document were the actual presentation slides, IP would be perfect. As a schedule announcement, it is a form of investor relations communication. Since it is not a formal report, and it is not a dividend, capital change, or management change, the closest fit among the specific categories related to investor engagement is Investor Presentation (IP), as it signals upcoming opportunities for investors to hear management's views. Alternatively, it could be RNS if it were purely administrative, but IP captures the intent better.
2017-03-23 English
EVOTEC AG TO REPORT FISCAL YEAR 2016 RESULTS ON 28 MARCH 2017
Report Publication Announcement Classification · 99% confidence The document is a news release dated March 21, 2017, announcing that EVOTEC AG will report its fiscal year 2016 results on March 28, 2017. It explicitly states the date and time for the conference call to discuss these results and provide an outlook for 2017. This is a classic announcement preceding the release of financial results, not the results themselves (which would likely be an ER or 10-K). Since it is an announcement about the upcoming release of financial results, it fits best under the category of Report Publication Announcement (RPA), as it is announcing *when* the report will be published and providing details for accessing the subsequent discussion (conference call). It is not the Earnings Release (ER) itself, which contains the actual figures.
2017-03-21 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and details information provided by Novo A/S regarding their shareholding in Evotec AG, specifically referencing the exceedance of a voting rights threshold pursuant to Art. 27a(1) WpHG (German Securities Trading Act). This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. Although the header mentions 'Voting Rights Announcements', the content is a specific notification about shareholding percentage changes, making MRQ the most precise fit among the provided codes. It is not a general regulatory filing (RNS) because it is highly specific to share ownership changes.
2017-03-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.